AMPH vs MCK

For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.

2% revenue growth year-over-year, versus -1. 7% for Amphastar Pharmaceuticals, Inc. (AMPH). Amphastar Pharmaceuticals, Inc. (AMPH) offers the better valuation at 11. 8x trailing P/E (7. 4x forward), making it the more compelling value choice. Analysts rate McKesson Corporation (MCK) a "Buy" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Amphastar Pharmaceuticals, Inc.

(AMPH) is the cheapest at 11. 8x versus McKesson Corporation at 28. 9x. On forward P/E, Amphastar Pharmaceuticals, Inc. is actually cheaper at 7. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Amphastar Pharmaceuticals, Inc. wins at 0. 05x versus McKesson Corporation's 0. 49x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +308.

4%, compared to +32. 4% for Amphastar Pharmaceuticals, Inc. (AMPH). Over 10 years, the gap is even starker: MCK returned +351. 9% versus AMPH's +103. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.

04β versus Amphastar Pharmaceuticals, Inc. 's 1. 40β — meaning AMPH is approximately 3142% more volatile than MCK relative to the S&P 500.

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.

2% versus -1. 7% for Amphastar Pharmaceuticals, Inc. (AMPH). On earnings-per-share growth, the picture is similar: McKesson Corporation grew EPS 14. 9% year-over-year, compared to -33. 7% for Amphastar Pharmaceuticals, Inc.. Over a 3-year CAGR, AMPH leads at 13. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Amphastar Pharmaceuticals, Inc.

(AMPH) is the more profitable company, earning 13. 6% net margin versus 0. 9% for McKesson Corporation — meaning it keeps 13. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMPH leads at 19. 5% versus 1. 2% for MCK. At the gross margin level — before operating expenses — AMPH leads at 49. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Amphastar Pharmaceuticals, Inc. (AMPH) is the more undervalued stock at a PEG of 0. 05x versus McKesson Corporation's 0. 49x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Amphastar Pharmaceuticals, Inc. (AMPH) trades at 7. 4x forward P/E versus 19. 1x for McKesson Corporation — 11. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MCK: 35. 3% to $1006. 50.

In this comparison, MCK (0.

4% yield) pays a dividend. AMPH does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

04), +351. 9% 10Y return). Both have compounded well over 10 years (MCK: +351. 9%, AMPH: +103. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AMPH is a small-cap deep-value stock; MCK is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.